Beam Therapeutics INC Form 4 insider transactions

Bethany J Cavanagh, SVP of Finance and Treasurer at Beam Therapeutics, sold 3,034 shares of common stock for $30.12 per share under a pre-arranged trading plan.

Beam Therapeutics' Chief Legal Officer, Christine Bellon, sold a total of 18,629 shares of common stock on January 15, 2026, through a pre-arranged 10b5-1 trading plan.

Beam Therapeutics' Chief Financial Officer, Sravan Kumar Emany, sold 6,294 shares of common stock at $27.1 per share to cover tax withholding obligations.

Beam Therapeutics' Chief Legal Officer, Christine Bellon, sold 1,254 shares of common stock at $27.1 per share to cover tax withholding obligations related to RSU vesting.

Beam Therapeutics' Chief Medical Officer, Amy Simon, was granted 12,500 restricted stock units, vesting over four years.

FMR LLC, a 10% owner of Beam Therapeutics Inc., reported the sale of 459 common shares at $26.68 per share on October 27, 2025.

FMR LLC, a 10% owner of Beam Therapeutics Inc., reported a disposition of 1,232,434 common shares via a gift or distribution.

Beam Therapeutics CEO John M. Evans sold 50,000 shares of common stock for over $1.2 million through a pre-arranged 10b5-1 trading plan.

Beam Therapeutics' SVP of Finance and Treasurer, Bethany J. Cavanagh, sold 467 shares of common stock at $24.53 per share to cover tax withholding obligations.

Beam Therapeutics' Chief Legal Officer, Christine Bellon, sold 373 shares of common stock to cover tax withholding obligations related to RSU vesting.

FMR LLC, a significant shareholder and director of Beam Therapeutics Inc., reported the sale of 48,374 common shares at $20.50 per share as part of a Rule 10b5-1 plan.

Beam Therapeutics' Chief Medical Officer, Amy Simon, reported the sale of 1,250 shares of common stock in early July 2025 through pre-arranged Rule 10b5-1 trading plans.

Beam Therapeutics Inc. Director Kathleen E. Walsh was granted 33,662 stock options with an exercise price of $17.15, aligning her incentives with long-term shareholder value.

Beam Therapeutics Inc. Director Christi Shaw was granted 33,662 stock options with an exercise price of $17.15, aligning her interests with long-term shareholder value.

Beam Therapeutics Inc. Director Mark Fishman was granted 33,662 stock options with an exercise price of $17.15 per share, aligning his interests with shareholder value.

Beam Therapeutics Inc. Director Carole Ho was granted 33,662 stock options with an exercise price of $17.15, as disclosed in a recent SEC Form 4 filing.

Beam Therapeutics Inc. Director John Maraganore has been granted 33,662 stock options with an exercise price of $17.15, vesting over the next year.

Beam Therapeutics Inc. Director Graham K. Cooper was granted 33,662 stock options with an exercise price of $17.15, aligning his interests with shareholder value.

Beam Therapeutics Inc. Director Chirfi Guindo was granted 33,662 stock options with an exercise price of $17.15 per share, vesting over the next year.

Christine Bellon, Chief Legal Officer of Beam Therapeutics, sold shares of common stock on April 1, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Beam Therapeutics CEO John M. Evans sold 30,663 shares of common stock on April 1, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Giuseppe Ciaramella, President of Beam Therapeutics, sold shares to cover tax withholding obligations related to vested restricted stock units.

Bethany J. Cavanagh, SVP of Finance and Treasurer at Beam Therapeutics, sold 3,015 shares of common stock on April 1, 2025, to cover tax withholding obligations.

Amy Simon, Chief Medical Officer of Beam Therapeutics, sold shares of common stock on April 1st and 2nd, 2025, to cover tax obligations and under a pre-arranged 10b5-1 trading plan.

Christine Bellon, Chief Legal Officer of Beam Therapeutics, was granted 20,000 restricted stock units (RSUs) on March 31, 2025, under the company's 2019 Equity Incentive Plan.

Amy Simon, Chief Medical Officer of Beam Therapeutics, reports acquiring 27,500 shares of common stock through restricted stock units.

Giuseppe Ciaramella, President of Beam Therapeutics, reports the acquisition of 35,000 shares of common stock through restricted stock units.

Bethany J Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics, reports the acquisition of 10,000 shares of common stock through restricted stock units.

CEO John M. Evans acquired 77,500 shares of Beam Therapeutics common stock on March 31, 2025, and holds over 1 million shares directly and another 103,000 indirectly.

Beam Therapeutics CEO John M. Evans files an amended SEC Form 4/A to disclose a prior stock option exercise that was inadvertently omitted from the original filing.